{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-042277","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.872489+00:00","generated_at":"2026-05-30T10:30:04.499595+00:00","sec_items":[],"event_type":"leadership","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Matinas BioPharma CDO resigns; CMO and VP Clinical Dev to assume duties","bullets":["Chief Development Officer Theresa Matkovits resigned effective October 23, 2024, to pursue another opportunity.","Resignation not due to material disagreement or change in company direction.","James J. Ferguson (CMO) and Susan Johansson (VP Clinical Dev) will fill her responsibilities.","Company continues to work toward partnership on MAT2203, its oral amphotericin B formulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-042277","json":"https://secwatch.observer/filing/0001493152-24-042277.json","markdown":"https://secwatch.observer/filing/0001493152-24-042277.md","text":"https://secwatch.observer/filing/0001493152-24-042277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224042277/0001493152-24-042277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224042277/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:30:04.499595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}